Introduction:
Fujifilm has announced an additional investment of $1.2 billion in its North Carolina cell culture CDMO (Contract Development and Manufacturing Organization) business. This investment is aimed at expanding the Fujifilm Diosynth Biotechnologies facility in Holly Springs, making it one of the largest cell culture biopharmaceutical CDMO facilities in North America.
- The $1.2 billion investment will be used to add 8 x 20,000 liters mammalian cell culture bioreactors to the planned facility, increasing its capacity for bulk drug substance production.
- The expansion will enable Fujifilm to construct identical large-scale production facilities in the US and Europe, allowing for seamless integration of drug manufacturing production regardless of location.
- The investment is in line with the growing demand for antibody drugs and the expansion of antibody drug conjugates (ADCs) and novel antibody drugs.
- The Holly Springs facility will incorporate sustainability initiatives, including the use of renewable energy sources to achieve net-zero operations.
- Upon completion, the facility is expected to achieve LEED Gold Certification and contribute to Fujifilm’s Sustainable Value Plan 2030.
Conclusion:
Fujifilm’s additional investment in its North Carolina CDMO facility demonstrates its commitment to meeting the growing demand for biopharmaceuticals. The expansion will not only increase production capacity but also ensure flexibility and sustainability in its operations. By constructing identical large-scale production facilities, Fujifilm aims to provide its partners with seamless drug manufacturing production capabilities. This investment aligns with the company’s long-term strategy and commitment to sustainability.
